Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi’s rimonabant from A to Z

Executive Summary

The Endocrinologic and Metabolic Drugs Advisory Committee will convene June 13 to discuss efficacy and safety data for Sanofi-Aventis' potential first-in-class obesity agent rimonabant. The proposed trade name for the CB-1 receptor agonist, previously known as Acomplia in the U.S., is Zimulti. The committee will review rimonabant's use as an adjunct to diet and exercise for obesity management in patients. Sanofi announced in February that FDA extended rimonabant's user fee date by three months, which would set a late July user fee action date (1"The Pink Sheet" Feb. 19, 2007, p. 19). The meeting will take place at the Hilton in Silver Spring, Md., from 8 a.m. to 5 p.m...

You may also be interested in...



Sanofi To Offer Broad Metabolic Syndrome Support Program For Acomplia

Sanofi-Aventis is positioning Acomplia as part of a comprehensive cardio-metabolic disease management program that includes patient and physician support services

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel